Loading...
•
Jun 30, 2022
Nuvation Bio Q2 2022 Earnings Report
Nuvation Bio reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $34.9 million, or $0.16 per share, for the three months ended June 30, 2022. The company's cash, cash equivalents and marketable securities totaled $703.8 million as of June 30, 2022.
Dosing is underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors.
The company has a strong financial position with cash runway through 2028.
Cash, cash equivalents and marketable securities totaled $703.8 million as of June 30, 2022.
David Liu, M.D., Ph.D., was appointed as Chief Medical Officer in July 2022, and Kerry Wentworth as Chief Regulatory Officer in May 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...